Sobi Will Present Gamifant Data in Rotterdam
The company will unveil new clinical analysis at the Histiocyte Society 2026 annual meeting this September.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to prioritize patient outcomes when presenting new clinical research data?
Sobi will present new clinical data regarding Gamifant for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) at the Histiocyte Society 2026 meeting. The event is scheduled to take place in Rotterdam from September 26-29, 2026.
Why it matters
The presentation highlights new survival outcomes for patients undergoing transplant procedures while using the antibody treatment. This analysis has earned recognition as one of the ten highest-scoring poster abstracts at the upcoming conference.
Sobi reported total revenue of SEK 28 billion in 2025. Gamifant, an anti-interferon gamma monoclonal antibody, is administered via a one-hour intravenous infusion.
The players
Sobi
This Swedish biopharmaceutical company focuses on developing treatments for rare diseases and reported 28 billion SEK in revenue for 2025.
Histiocyte Society
This international organization is dedicated to research and education regarding histiocytic disorders.
The details
The upcoming presentation includes a pooled analysis focusing on survival outcomes for patients before and after transplantation. Additionally, Sobi has received a nomination for the Robert J. Arceci Prize for Best Poster in conjunction with the conference.
Timeline
Sobi reported revenue of SEK 28 billion for the full year 2025.
The Histiocyte Society 2026 annual meeting occurs from September 26-29, 2026.
Market Landscape
The presentation follows the historical precedence of academic recognition established by the Robert J. Arceci Prize for Best Poster. The nomination reflects the company's ongoing efforts to gain clinical validation for its rare disease portfolio within a competitive global market.
Gamifant remains an approved treatment option for adult and pediatric primary HLH patients in the United States. Future updates from these clinical analyses may further inform long-term care and survival expectations for patients receiving the infusion therapy.
The takeaway
Clinicians and patients often rely on such pooled clinical data to understand the long-term effectiveness of monoclonal antibody treatments after transplant. The data presentation at this year's meeting serves as a critical update on the safety and efficacy profile of the drug.
Further reading
Learn more about the latest developments in the Healthcare sector.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical companies to prioritize patient outcomes when presenting new clinical research data?
